218 related articles for article (PubMed ID: 35923470)
1. Management Strategies of Breast Cancer Patients with
Edaily S; Abdel-Razeq H
Onco Targets Ther; 2022; 15():815-826. PubMed ID: 35923470
[TBL] [Abstract][Full Text] [Related]
2. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
[TBL] [Abstract][Full Text] [Related]
4. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
5. Fanconi Anaemia, Childhood Cancer and the
Woodward ER; Meyer S
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680915
[TBL] [Abstract][Full Text] [Related]
6. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
7. The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in
Larionov A; Fewings E; Redman J; Goldgraben M; Clark G; Boice J; Concannon P; Bernstein J; Conti DV; The Wecare Study Collaborative Group ; Tischkowitz M
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672364
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
11.
Lee A; Moon BI; Kim TH
Ann Lab Med; 2020 Mar; 40(2):114-121. PubMed ID: 31650727
[TBL] [Abstract][Full Text] [Related]
12. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic acinar cell carcinoma is associated with
Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
[TBL] [Abstract][Full Text] [Related]
14. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
16. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
18. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
[TBL] [Abstract][Full Text] [Related]
19. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
[TBL] [Abstract][Full Text] [Related]
20. Patterns and Prevalence of
Abdel-Razeq H; Tamimi F; Abujamous L; Edaily S; Abunasser M; Bater R; Salama O
Cancer Manag Res; 2021; 13():4597-4604. PubMed ID: 34135636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
